BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Apollo vs. Artemis: What to know about NASA's return to the moon - 2How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
- 3Rubble, mud and hair: How to rebuild a home in Gaza
- 4Farewell, comet 3I/ATLAS! Interstellar visitor heads for the outer solar system after its closest approach to Earth
- 5Floods, Landslides Triggered By Heavy Rain In Afghanistan Leave 77 Dead In 10 days, Authorities Say
- Strength training is crucial after menopause. How to make the most of your workouts
- Turning into a Distributed Writer: My Composing Process
- Germany unveils rescue plan for struggling chemical sector
- Poland open to German troops to help secure Ukraine ceasefire
- Venus shines at its best in spring and summer 2026 — here's what to look for
- KJ Apa stars as Jimmy Stewart in new biopic: See his transformation
- Did Japan’s PM Actually Back the Memecoin Bearing Her Name?
- Exploring ways to reduce the impact of space junk on Earth
- Moon-bound Artemis II astronauts enjoy a relaxed day in space
